Reactome: A Curated Pathway Database

FGFR3 mutants bind and are inactivated by tyrosine kinase inhibitors

Stable Identifier
R-HSA-2077420
Type
Reaction
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
Summation

FGFR3 has been shown to be a target of a range of different tyrosine kinase inhibitors, including those restricted to in vitro use as well as a number that are currently in clinical trials for therapeutic use (see for instance, Paterson, 2004; Trudel, 2004; Trudel, 2005; Grand, 2004, Chen, 2005; Bernard-Pierrot, 2006; http::/clinicaltrials.gov). There are also two anti-FGFR3 antibodies that have shown preliminary promise in cancer cell lines or mouse models (Qing, 2009; Trudel, 2006).

Literature References
Participants
Participant Of
Disease
Diseases
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer